Purple Biotech (PPBT) Change in Accured Expenses (2018 - 2026)
Purple Biotech (PPBT) posted quarterly Change in Accured Expenses of $296000.0 for Q1 2026, up 127.69% year-over-year from $130000.0 in Q1 2025, and down 2.95% quarter-over-quarter from $305000.0 in Q4 2025.
Purple Biotech (PPBT) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Change in Accured Expenses for 9 consecutive years, with $296000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 127.69% year-over-year to $296000.0; the TTM figure through Mar 2026 stood at $371000.0 (up 123.92% YoY), while the FY2025 annual figure was $205000.0, up 108.72% from the prior year.
- Change in Accured Expenses declined to $296000.0 in Q1 2026 per PPBT's latest filing, from $305000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.7 million in Q1 2022 and bottomed at -$1.5 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$46764.7 across 5 years, with a median of -$2000.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses plunged 2106.06% — and 2025, when it jumped 145.25%.
- Purple Biotech's Change in Accured Expenses stood at $1.6 million in 2022, then tumbled by 89.07% to $179000.0 in 2023, then slumped by 476.54% to -$674000.0 in 2024, then surged by 145.25% to $305000.0 in 2025, then dropped by 2.95% to $296000.0 in 2026.
- Business Quant data shows PPBT's Change in Accured Expenses at $296000.0 in Q1 2026, $305000.0 in Q4 2025, and -$2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Purple Biotech | 130.35 | 130.35 | - | -66,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 296,000.00 |
| Mar 31, 2026 | 296,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Dec 31, 2025 | 305,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -228,000.00 |
| Jun 30, 2025 | -228,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | -674,000.00 |
| Dec 31, 2024 | -674,000.00 |
| Sep 30, 2024 | -345,000.00 |
| Sep 30, 2024 | -345,000.00 |
| Jun 30, 2024 | -662,000.00 |
| Jun 30, 2024 | -662,000.00 |
| Mar 31, 2024 | -671,000.00 |
| Mar 31, 2024 | -671,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |